Our early cancer detection test displays high performance in differentiating early lung cancer patients from healthy individuals, and detecting Stage I lung cancers and tumors < 10mm! Learn more below.
#earlycancerdetection #lungcancer
prnewswire.com/news-releases/
Follow
Geneseeq Technology Inc.
@GeneseeqInc
Geneseeq is a research-driven company providing cutting-edge NGS technology to accelerate precision cancer care.
Geneseeq Technology Inc.’s Tweets
Happy to announce our partnership with Brazilian hospital Hospital de Base to build an #NGS cancer genomics lab in-house!
#cancertesting
An overview of our high-performing early cancer detection program.
#precisiononcology #earlydetection
Excited to be back at #ASCO22? We participated in the science behind 7 posters and 1 oral this year. Read more below and see you in Chicago! #precisiononcology
A study using our comprehensive gene panel Geneseeqprime, provides an overview of kinase IGRs in a large #lungcancer cohort and examines real-world survival outcomes of patients.
esmoopen.com/article/S2059-
Our DECIPHER study on #livercancer early detection was published in . The study demonstrates excellent performance in early #cancerscreening for liver cancer population while distinguishing ICC from HCC, using #liquidbiopsy.
Our DECIPHER early cancer detection program published a study in the Hepatology journal on detecting liver cancer early.
In the study, the liver cancer screening tests demonstrated high sensitivity and specificity.
na.geneseeq.com/geneseeqs-canc
#Cancer #earlydetection
The study was conducted to demonstrate the status of perioperative ctDNA positivity is significantly associated with disease recurrence and long-term patient outcomes for resectable #NSCLC.
Show this thread
A recent study we worked on shows that #ctDNA surveillance shows to predict tumor relapse earlier than traditional medical images with a lead time of 8.71 months!
#liquidbiopsy
1
Show this thread
Read about our newest study on using our comprehensive gene panel to characterize insightful tumor biomarkers and guide personalized adjuvant treatment for non-small-cell lung cancer patients!
#cancerresearch #NSCLC
na.geneseeq.com/geneseeq-colla
Geneseeq and collaborators published a study on the genomic landscape of metastatic lung adenocarcinomas from clinical sequencing data of over 6000 samples!
#CancerResearch
sciencedirect.com/science/articl
Geneseeq and collaborators published a study with the largest early-stage colorectal cancer (stage 0/1) study cohort on #earlydetection.
The study yielded encouraging results!
Read more about the study below:
na.geneseeq.com/geneseeq-study
1
Our new study on repair-associated DNA polymerases in a cohort of 12,266 patients across 16 different tumor types demonstrates pathogenicity and additive prognostic value of polymerase and DDR pathway gene alterations.
jitc.bmj.com/content/9/9/e0
#cancerresearch #geneseeq
Geneseeq will be presenting the results of a multi-center prospective study on the dynamic monitoring of ctDNA in children’s lymphoma at #SIOP2021!
Follow the conference for more details.
siop-congress.org
We are excited to announce our strategic collaboration with to advance cancer care in bringing products through the R&D cycle further, and faster.
#cancercare #precisiononcology
newswire.ca/en/releases/ar
1
Congratulations to our R&D team for winning the Best Poster Award at EMSO 2021 for their work in detecting minimal residual disease (MRD) in non-small cell lung cancer (NSCLC)!
#MRDdetection #CancerResearch #ESMO21
1
We are excited to announce that our minimal residual disease (MRD) program, CALIBRATE, is also available.
Learn more about what we are up to here: lnkd.in/eDsAw-QK
#MRD #GeneseeqPrograms
We are proud to announce that our early cancer detection program, DECIPHER, is now available.
Learn more about what we are up to here: lnkd.in/eDsAw-QK
#EarlyCancerDetection #GeneseeqPrograms
#lungcancer is the leading cause of cancer-related death worldwide, with a 5-year survival rate of less than 21%.
Read about our study on kinase fusions which represent an important type of genetic alteration that promotes oncogenesis in lung cancer.
nature.com/articles/s4169
Getting ready to present a mini oral tomorrow covering the topic of Detecting Stage I Lung Cancer with High Sensitivity Using Genome-wide Multi-dimensional Fragmentomic Profiles of Cell-Free DNA (cfDNA) at #WCLC21
na.geneseeq.com/geneseeq-prese
We continue to work on ctDNA minimal residual disease (MRD) monitoring for colorectal cancer patients since 2017. Read about our new study in .
#MRD #cancerresearch #liquidbiopsy
na.geneseeq.com/geneseeq-study
1
2
Read about our study on arm aneuploidy in lung carcinoma. #lungcancerresearch
We are proud to be the only designated next-generation sequencing (NGS) testing center of the first global regulatory approval for sovalitinib by
and #precisiononcology
Micropapillary adenocarcinoma is a very aggressive subtype of lung cancer and is associated with a very poor prognosis.
We identified some rare genetic events that may drive micropapillary tumor progression in our new study below:
Learn more about using DNA methylation markers to predict the risk of liver metastasis and facilitate the decision for adjuvant chemotherapy in our new study below.
lepigeneticsjournal.biomedcentral.com/articles/10.11
#clinicalepigeneticsjournal #precisiononcology #ngs
1
We are excited to be presenting at this year's Annual Meeting!
Read about the study summaries here: na.geneseeq.com/geneseeq-prese
Access the abstracts here: meetinglibrary.asco.org/results?meetin
#asco2021 #oncologyresearch
Check out our new study on predicting colorectal cancer relapse by monitoring ctDNA. Published in the Journal of Hematology and Oncology
#CancerResearch
1
1
Read about our new study on age-dependent genetic alterations in younger versus older lung cancer patients.
So are there differences between the two patient groups?
The answer is yes.
#lungcancer #precisiononcology
We are excited to announce our strategic collaboration with to build a Bio-Diagnostics Innovation Center in Guangzhou, China.
Learn more:
3
Geneseeq is presenting novel translational research results through ePosters at Annual Meeting 2021, with a focus on rare genomic alterations in various types of cancer.
ePoster numbers: 2211, 2166, 2249, 2041, 2210
Access through:abstractsonline.com/pp8/#!/9325
#AACR21
Geneseeq (), to develop and commercialize comprehensive cancer in-vitro diagnostic NGS kit in China cancerletter.com/articles/20210
1
1
Check out our new study published in the Journal of Thoracic Oncology (JTO) on lung cancer early detection, by diving into the molecular mechanisms and evolutionary patterns of tumors and metastases.
#lungcancerscreening #oncologyresearch
We are excited to extend our collaboration with to develop assays on our newly approved NextSeq® 550Dx in China. Together, we will develop comprehensive cancer IVD kits to promote #NGS as the standard of care for Chinese patients.
bit.ly/3lotU00
1
6
15
We are pleased to announce a partnership with to develop and commercialize in-vitro diagnostic (IVD) kits for cancer patients to produce accurate and rapid results.
newswire.ca/en/releases/ar
#precisiononcology #ngs
Sharing an insightful report on the progress against cancer in 2021, shining a spotlight on the importance to increase precision medicine research and treatment approaches.
#IAmAndIWill #precisiononcology #WorldCancerDay
ascopubs.org/doi/full/10.12
1